Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Allarity Therapeutics, Inc.ALLR · Entity 7594 | See Remarks | January 22, 2026 | October 09, 2026 |
| IN8BIO, INC.INAB · Entity 7941 | Director | May 09, 2026 | May 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Allarity Therapeutics, Inc.
Report date January 22, 2026 · Filed October 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 73,028 |
Reported balance
After 2026-01-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-22 · Exercise / conversion · Acquired 48,147 · Balance 73,028 F1: Restricted stock units convert into common stock on a one-for-one basis. |
| Common StockSEC Table I · non-derivative | Direct | 55,214 |
Reported balance
After 2026-01-22 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-01-22 · Tax withholding · Disposed 17,814 · Balance 55,214 F3: Represents shares withheld by the Issuer to satisfy tax withholding obligations arising upon the vesting and settlement of restricted stock units. The shares were withheld based on the fair market value of the Issuer's common stock on the applicable vesting date. |
| Common StockSEC Table I · non-derivative | Direct | 94,708 |
Reported balance
After 2026-09-30 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-09-30 · Exercise / conversion · Acquired 39,494 · Balance 94,708 F1: Restricted stock units convert into common stock on a one-for-one basis. |
| Common StockSEC Table I · non-derivative | Direct | 80,095 |
Reported balance
After 2026-09-30 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-09-30 · Tax withholding · Disposed 14,613 · Balance 80,095 F3: Represents shares withheld by the Issuer to satisfy tax withholding obligations arising upon the vesting and settlement of restricted stock units. The shares were withheld based on the fair market value of the Issuer's common stock on the applicable vesting date. F5: The 381,644 amount previously reported in column 5 of Table I of the Reporting Person's Form 4/A filed April 30, 2026 combined issued shares of common stock and unvested restricted stock units and did not reflect the 17,814 shares withheld on January 22, 2026. This Form 4 reports issued shares of common stock in Table I and unvested restricted stock units separately in Table II. After giving effect to the January 22, 2026 vesting and withholding and the January 28, 2026 restricted stock unit grant, the correct balances were 55,214 shares of common stock and 308,616 restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 175,283 |
Reported balance
After 2026-01-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-01-22 · Exercise / conversion · Disposed 48,147 · Balance 175,283 F1: Restricted stock units convert into common stock on a one-for-one basis. F2: On September 30, 2024 and January 22, 2025, the Reporting Person was granted 118,483 and 144,441 restricted stock units, respectively, which vest in three equal annual installments beginning on the first anniversary of the applicable grant date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 269,122 |
Reported balance
After 2026-09-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-30 · Exercise / conversion · Disposed 39,494 · Balance 269,122 F1: Restricted stock units convert into common stock on a one-for-one basis. F2: On September 30, 2024 and January 22, 2025, the Reporting Person was granted 118,483 and 144,441 restricted stock units, respectively, which vest in three equal annual installments beginning on the first anniversary of the applicable grant date. F4: The amount reported in column 9 reflects 175,283 restricted stock units outstanding following the January 22, 2026 settlement, plus 133,333 restricted stock units granted on January 28, 2026 and previously reported, less 39,494 restricted stock units settled on September 30, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: On September 30, 2024 and January 22, 2025, the Reporting Person was granted 118,483 and 144,441 restricted stock units, respectively, which vest in three equal annual installments beginning on the first anniversary of the applicable grant date.
F3: Represents shares withheld by the Issuer to satisfy tax withholding obligations arising upon the vesting and settlement of restricted stock units. The shares were withheld based on the fair market value of the Issuer's common stock on the applicable vesting date.
F4: The amount reported in column 9 reflects 175,283 restricted stock units outstanding following the January 22, 2026 settlement, plus 133,333 restricted stock units granted on January 28, 2026 and previously reported, less 39,494 restricted stock units settled on September 30, 2026.
F5: The 381,644 amount previously reported in column 5 of Table I of the Reporting Person's Form 4/A filed April 30, 2026 combined issued shares of common stock and unvested restricted stock units and did not reflect the 17,814 shares withheld on January 22, 2026. This Form 4 reports issued shares of common stock in Table I and unvested restricted stock units separately in Table II. After giving effect to the January 22, 2026 vesting and withholding and the January 28, 2026 restricted stock unit grant, the correct balances were 55,214 shares of common stock and 308,616 restricted stock units.
IN8BIO, INC.
Report date May 09, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.58 · Expires 2036-05-09 | Direct | 22,000 |
Reported balance
After 2026-05-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-09 · Grant · Acquired 22,000 · Balance 22,000 F1: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 9, 2026; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 9, 2026; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 9, 2026 21:12 UTC | Allarity Therapeutics, Inc. ALLR · Entity 7594 | Exercise / conversionRestricted Stock Units · Derivative | 39,494 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-108573 · ownership.xml · derivative · entry 6 Graff Jeremy R. · CIK 0001975028 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 269,122 Underlying: Common Stock · 39,494 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On September 30, 2024 and January 22, 2025, the Reporting Person was granted 118,483 and 144,441 restricted stock units, respectively, which vest in three equal annual installments beginning on the first anniversary of the applicable grant date. F2 · derivative.expiration_date: On September 30, 2024 and January 22, 2025, the Reporting Person was granted 118,483 and 144,441 restricted stock units, respectively, which vest in three equal annual installments beginning on the first anniversary of the applicable grant date. F4 · balance_after: The amount reported in column 9 reflects 175,283 restricted stock units outstanding following the January 22, 2026 settlement, plus 133,333 restricted stock units granted on January 28, 2026 and previously reported, less 39,494 restricted stock units settled on September 30, 2026. Read SEC document |
| September 30, 2026 Filed Oct 9, 2026 21:12 UTC | Allarity Therapeutics, Inc. ALLR · Entity 7594 | Tax withholdingCommon Stock | 14,613 | $0.97 | $14,174.61 |
DisclosureSEC source: 0001213900-26-108573 · ownership.xml · nonDerivative · entry 4 Graff Jeremy R. · CIK 0001975028 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,095 F3 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations arising upon the vesting and settlement of restricted stock units. The shares were withheld based on the fair market value of the Issuer's common stock on the applicable vesting date. F5 · balance_after: The 381,644 amount previously reported in column 5 of Table I of the Reporting Person's Form 4/A filed April 30, 2026 combined issued shares of common stock and unvested restricted stock units and did not reflect the 17,814 shares withheld on January 22, 2026. This Form 4 reports issued shares of common stock in Table I and unvested restricted stock units separately in Table II. After giving effect to the January 22, 2026 vesting and withholding and the January 28, 2026 restricted stock unit grant, the correct balances were 55,214 shares of common stock and 308,616 restricted stock units. Read SEC document |
| September 30, 2026 Filed Oct 9, 2026 21:12 UTC | Allarity Therapeutics, Inc. ALLR · Entity 7594 | Exercise / conversionCommon Stock | 39,494 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-26-108573 · ownership.xml · nonDerivative · entry 3 Graff Jeremy R. · CIK 0001975028 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| May 09, 2026 Filed May 12, 2026 20:30 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantStock Option (right to buy) · Derivative | 22,000 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001975028-26-000002 · form4-05122026_040505.xml · derivative · entry 1 Graff Jeremy R. · CIK 0001975028 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2036-05-09 F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 9, 2026; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| January 28, 2026 Filed Apr 30, 2026 19:38 UTC Amendment | Allarity Therapeutics, Inc. ALLR · Entity 7594 | GrantCommon Stock | 133,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-050133 · ownership.xml · nonDerivative · entry 1 Graff Jeremy R. · CIK 0001975028 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 381,644 F1 · shares: The restricted stock units, or RSUs, granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, will vest in equal one-third installments on the first, second, and third anniversary of the grant, subject to the Reporting Person's continued relationship with the Issuer through each such date. Read SEC document |
| January 22, 2026 Filed Oct 9, 2026 21:12 UTC | Allarity Therapeutics, Inc. ALLR · Entity 7594 | Exercise / conversionRestricted Stock Units · Derivative | 48,147 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-108573 · ownership.xml · derivative · entry 5 Graff Jeremy R. · CIK 0001975028 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,283 Underlying: Common Stock · 48,147 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On September 30, 2024 and January 22, 2025, the Reporting Person was granted 118,483 and 144,441 restricted stock units, respectively, which vest in three equal annual installments beginning on the first anniversary of the applicable grant date. F2 · derivative.expiration_date: On September 30, 2024 and January 22, 2025, the Reporting Person was granted 118,483 and 144,441 restricted stock units, respectively, which vest in three equal annual installments beginning on the first anniversary of the applicable grant date. Read SEC document |
| January 22, 2026 Filed Oct 9, 2026 21:12 UTC | Allarity Therapeutics, Inc. ALLR · Entity 7594 | Tax withholdingCommon Stock | 17,814 | $1.18 | $21,020.52 |
DisclosureSEC source: 0001213900-26-108573 · ownership.xml · nonDerivative · entry 2 Graff Jeremy R. · CIK 0001975028 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,214 F3 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations arising upon the vesting and settlement of restricted stock units. The shares were withheld based on the fair market value of the Issuer's common stock on the applicable vesting date. Read SEC document |
| January 22, 2026 Filed Oct 9, 2026 21:12 UTC | Allarity Therapeutics, Inc. ALLR · Entity 7594 | Exercise / conversionCommon Stock | 48,147 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-26-108573 · ownership.xml · nonDerivative · entry 1 Graff Jeremy R. · CIK 0001975028 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,028 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 07, 2026 Filed Jan 16, 2026 21:13 UTC | Allarity Therapeutics, Inc. ALLR · Entity 7594 | GrantCommon Stock | 133,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-005146 · ownership.xml · nonDerivative · entry 1 Graff Jeremy R. · CIK 0001975028 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 381,644 F1 · shares: The restricted stock units, or RSUs, granted on January 7, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, will vest in equal one-third installments on the first, second, and third anniversary of the grant, subject to the Reporting Person's continued relationship with the Issuer through each such date. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:05 UTC | Allarity Therapeutics, Inc. ALLR · Entity 7594 | Exercise / conversionRestricted Stock Units · Derivative | 39,494 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-095391 · ownership.xml · derivative · entry 3 Graff Jeremy R. · CIK 0001975028 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 223,430 Underlying: Common Stock · 39,494 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On September 30, 2024 and January 22, 2025, the Reporting Person was granted 118,483 and 144,441 restricted stock units, respectively, which vest in three equal annual installments beginning on the first anniversary of the applicable grant date. F2 · derivative.expiration_date: On September 30, 2024 and January 22, 2025, the Reporting Person was granted 118,483 and 144,441 restricted stock units, respectively, which vest in three equal annual installments beginning on the first anniversary of the applicable grant date. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:05 UTC | Allarity Therapeutics, Inc. ALLR · Entity 7594 | Tax withholdingCommon Stock | 14,613 | $1.58 | $23,088.54 |
DisclosureSEC source: 0001213900-25-095391 · ownership.xml · nonDerivative · entry 2 Graff Jeremy R. · CIK 0001975028 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,881 Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:05 UTC | Allarity Therapeutics, Inc. ALLR · Entity 7594 | Exercise / conversionCommon Stock | 39,494 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-25-095391 · ownership.xml · nonDerivative · entry 1 Graff Jeremy R. · CIK 0001975028 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,494 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| May 08, 2025 Filed May 12, 2025 20:15 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantStock Option (right to buy) · Derivative | 63,150 | $0.00 Strike: $0.17 | $0.00 |
DisclosureSEC source: 0001415889-25-012653 · form4-05122025_040518.xml · derivative · entry 1 Graff Jeremy R. · CIK 0001975028 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,150 Underlying: Common Stock · 63,150 shares Expires 2035-05-08 F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 8, 2025; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| April 27, 2025 Filed May 8, 2025 00:45 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantSeries B Warrants (right to buy) · Derivative | 2,049 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0001415889-25-012292 · form4-05072025_080513.xml · derivative · entry 2 Graff Jeremy R. · CIK 0001975028 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,049 Underlying: Common Stock · 2,049 shares Expires 2028-12-13 F1 · kind: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share. F1 · price: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share. F2 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| April 27, 2025 Filed May 8, 2025 00:45 UTC | IN8BIO, INC. INAB · Entity 7941 | Disposition to issuerSeries B Warrants (right to buy) · Derivative | 2,049 | Not disclosed Strike: $1.50 | Not disclosed |
DisclosureSEC source: 0001415889-25-012292 · form4-05072025_080513.xml · derivative · entry 1 Graff Jeremy R. · CIK 0001975028 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,049 shares Expires 2028-12-13 F1 · kind: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share. F1 · price: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share. F3 · price: The reported securities are included within 2,049 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 2,049 shares of common stock. F2 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| January 22, 2025 Filed Jan 24, 2025 21:18 UTC | Allarity Therapeutics, Inc. ALLR · Entity 7594 | GrantCommon Stock | 144,441 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-001808 · rdgdoc.xml · nonDerivative · entry 1 Graff Jeremy R. · CIK 0001975028 · CDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 262,924 F1 · shares: The restricted stock units, or RSUs, granted on January 22, 2025 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, will vest in equal one-third installments on the first, second, and third anniversary of the grant, subject to the Reporting Person's continued relationship with the Issuer through each such date. Read SEC document |
| December 19, 2024 Filed Dec 23, 2024 21:15 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantStock Option (right to buy) · Derivative | 47,697 | $0.00 Strike: $0.24 | $0.00 |
DisclosureSEC source: 0001415889-24-030065 · form4-12232024_041220.xml · derivative · entry 1 Graff Jeremy R. · CIK 0001975028 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,697 Underlying: Common Stock · 47,697 shares Expires 2034-12-19 F1 · derivative.exercise_date: The shares subject to the option shall vest on December 19, 2025, subject to the Reporting Person continuing to provide service on such date. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 21:34 UTC | Allarity Therapeutics, Inc. ALLR · Entity 7594 | GrantCommon Stock | 118,483 | $2.11 | $249,999.13 |
DisclosureSEC source: 0001213900-24-084163 · ownership.xml · nonDerivative · entry 1 Graff Jeremy R. · CIK 0001975028 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,483 F1 · shares: The Reporting Person was granted 118,483 restricted stock units, or RSUs, in connection with the Reporting Person's appointment as President and Chief Development Officer of the Issuer. The RSUs will vest in equal one-third installments on the first, second, and third anniversary of the Reporting Person's appointment, subject to the Reporting Person's continued relationship with the Issuer through each such date. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 21:00 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantStock Option (right to buy) · Derivative | 33,650 | $0.00 Strike: $1.47 | $0.00 |
DisclosureSEC source: 0001415889-24-016968 · form4-06142024_050612.xml · derivative · entry 1 Graff Jeremy R. · CIK 0001975028 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,650 Underlying: Common Stock · 33,650 shares Expires 2034-06-12 F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on July 12, 2024; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 13:27 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantSeries B Warrants (right to buy) · Derivative | 2,049 | Not disclosed Strike: $1.50 | Not disclosed |
DisclosureSEC source: 0001209191-23-058721 · doc4.xml · derivative · entry 3 Graff Jeremy R. · CIK 0001975028 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,049 Underlying: Common Stock · 2,049 shares Expires 2028-12-13 F1 · price: The reported securities are included within 2,049 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 2,049 shares of common stock. F2 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 13:27 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantSeries A Warrants (right to buy) · Derivative | 2,049 | Not disclosed Strike: $1.25 | Not disclosed |
DisclosureSEC source: 0001209191-23-058721 · doc4.xml · derivative · entry 2 Graff Jeremy R. · CIK 0001975028 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,049 Underlying: Common Stock · 2,049 shares Expires 2025-06-13 F1 · price: The reported securities are included within 2,049 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 2,049 shares of common stock. F2 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 13:27 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantCommon Stock | 2,049 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-058721 · doc4.xml · nonDerivative · entry 1 Graff Jeremy R. · CIK 0001975028 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,549 F1 · price: The reported securities are included within 2,049 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 2,049 shares of common stock. Read SEC document |
| September 13, 2023 Filed Sep 15, 2023 20:51 UTC | IN8BIO, INC. INAB · Entity 7941 | PurchaseCommon Stock | 2,500 | $0.95 | $2,375.00 |
DisclosureSEC source: 0001209191-23-049607 · doc4.xml · nonDerivative · entry 1 Graff Jeremy R. · CIK 0001975028 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 23:43 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantStock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-23-038120 · doc4.xml · derivative · entry 1 Graff Jeremy R. · CIK 0001975028 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2033-06-15 F1 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on July 15, 2023 and will be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| May 01, 2023 Filed May 3, 2023 20:55 UTC | IN8BIO, INC. INAB · Entity 7941 | GrantStock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001209191-23-027027 · doc4.xml · derivative · entry 1 Graff Jeremy R. · CIK 0001975028 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2033-05-01 F1 · derivative.exercise_date: One thirty-sixth (1/36th) of the shares subject to the option shall vest in equal monthly installments commencing on June 1, 2023, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.